Game-Changer for IPF: Inhaled Tyvaso Preserves Lung Function in Major TETON-1 Study

The United Therapeutics TETON-1 trial shows that inhaled Tyvaso preserves lung function by 130 mL versus placebo and reduces disease progression. Positive results were seen across all patient groups, with an FDA filing planned for this summer.